Can antibodies to seasonal coronaviruses protect against SARS-CoV-2?
COVID-19 is not the world's first exposure to a coronavirus. With at least six previous exposures to various types of coronaviruses, researchers are exploring if antibodies created during earlier infection with coronaviruses can help to fight off SARS-CoV-2 infection. The findings of the study were published in Cell Reports Medicine on January 19.  Discuss
Gritstone licenses lipid nanoparticle tech for COVID-19 vaccine
Gritstone Oncology and Genevant Sciences have entered into an agreement to develop and commercialize self-amplifying RNA vaccines against SARS-CoV-2.
Akron, Octapharma ink deal to make human AB serum
Akron Biotech and Octapharma have signed an exclusive agreement to produce virally inactivated human AB serum to bring it to the cell therapy market.
Gritstone advances second-generation COVID-19 vaccine candidate
Gritstone Oncology is advancing the development of a second-generation vaccine against SARS-CoV-2 with potential for both prolonged protection and potency against spike protein mutations.
MIT researchers use natural language processing to analyze viral evolution
In a breakthrough that could guide the development of targeted vaccines, Massachusetts Institute of Technology (MIT) researchers used natural language processing methods lifted from the field of computational linguistics to analyze the viral protein sequence data of influenza A, HIV, and SARS-CoV-2 to identify regions within the genomes of those viruses that are most vulnerable to mutation. The results were published in a new study in Science on January 15.  Discuss
Startup Creative Bio launches cell culture portfolio
Creative Bio has launched a portfolio of cell culture tools that it hopes will be useful during the COVID-19 pandemic.
IGM Biosciences licenses SARS-CoV-2 antibodies from AvantGen
AvantGen has licensed a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
ImmunityBio licenses oral vaccine tech from IosBio
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.
Codagenix starts phase I trial for COVID-19 vaccine in U.K.
The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-VAC, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.
How can biopharma innovation be maintained after COVID-19?
Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel of speakers discussed these questions during a January 7 advance session of the Biotech Showcase, a virtual event to be held January 11-15.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter